hydroxychloroquine has been researched along with Central Nervous System Lupus in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the case of a male patient with SLE who presented with an exacerbation of bipolar disorder triggered by chloroquine." | 7.80 | Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report. ( Bienkowski, P; Bogaczewicz, A; Bogaczewicz, J; Robak, E; Sobów, T; Sysa-Jedrzejowska, A; Wozniacka, A, 2014) |
| " We report the case of a male patient with SLE who presented with an exacerbation of bipolar disorder triggered by chloroquine." | 3.80 | Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report. ( Bienkowski, P; Bogaczewicz, A; Bogaczewicz, J; Robak, E; Sobów, T; Sysa-Jedrzejowska, A; Wozniacka, A, 2014) |
| "Acute cerebellar ataxia is a rare primary manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE)." | 2.72 | Cerebellar ataxia as a primary manifestation of neuropsychiatric systemic lupus erythematosus. ( Fernandez, MLL; Reyes, NGD; Sy, MCC; Zamora, GT, 2021) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brites, L | 1 |
| Rodrigues, M | 1 |
| Luis, M | 1 |
| Santiago, M | 1 |
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Sy, MCC | 1 |
| Reyes, NGD | 1 |
| Zamora, GT | 1 |
| Fernandez, MLL | 1 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| Teng, YKO | 1 |
| de Leeuw, K | 1 |
| Bijl, M | 1 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Bultink, IEM | 1 |
| Kamphuis, S | 1 |
| Bogaczewicz, J | 1 |
| Sobów, T | 1 |
| Bogaczewicz, A | 1 |
| Robak, E | 1 |
| Bienkowski, P | 1 |
| Sysa-Jedrzejowska, A | 1 |
| Wozniacka, A | 1 |
| Harten, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Central Nervous System Lupus
| Article | Year |
|---|---|
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Cerebellar ataxia as a primary manifestation of neuropsychiatric systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Antimalarials; Cerebellar Ataxia; Female; Gait Analysis; Headache; | 2021 |
4 other studies available for hydroxychloroquine and Central Nervous System Lupus
| Article | Year |
|---|---|
New onset weakness in the face and arm.
Topics: Adult; Arm; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Vasculitis, Cen | 2020 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
Topics: Adult; Antimalarials; Bipolar Disorder; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus | 2014 |
[Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antirheumatic Agents; Azathioprine; Coumarins; Cycloph | 2003 |